ABBV vs KO Stock Comparison: AI Score, Valuation, Performance and Upside
ABBV vs KO pits a higher-growth, higher-yield pharmaceutical company against the quintessential defensive consumer staple. AbbVie offers a larger dividend yield and stronger near-term earnings growth driven by Skyrizi and Rinvoq, but carries pharma-specific risks like patent cliffs and pipeline dependency. Coca-Cola offers a slower, steadier growth profile with one of the most durable brand moats in the world and a longer streak of dividend increases.
AbbVie suits investors comfortable with biopharma-specific risk in exchange for higher growth and yield, betting that management can keep replacing maturing drugs with new blockbusters the way it did with Humira. Coca-Cola suits investors who prioritize predictability and want a lower-volatility compounder that has weathered recessions, inflation cycles, and shifting consumer tastes for over a century.
ABBV holds the edge across 4 of 5 key metrics in this comparison. KO has delivered stronger 1-year price return (+31.15% vs +18.88%), though ABBV has the better forward P/E setup (15.79x vs 25.43x for KO). ABBV leads on both revenue growth (10.20%) and operating margin (40.03%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies similar upside for both: +7.85% for ABBV and +5.62% for KO.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want a high current dividend yield paired with double-digit earnings growth
- Believe management can replicate its post-Humira pivot with future pipeline assets
- Are comfortable with biopharma-specific risks like patent cliffs and clinical trial outcomes
- Want exposure to immunology, aesthetics, and neuroscience growth markets
- Prioritize capital preservation and multi-decade dividend reliability over growth
- Want exposure to global consumer demand without pharma-specific regulatory risk
- Prefer a capital-light business model with high, stable margins
- Are building a core defensive holding for a diversified long-term portfolio
| Metric | ABBV | KO |
|---|---|---|
| AI scorei | 53.0 | 51.7 |
| AI ranki | #316 | #385 |
| Latest closei | $264.48 | $87.12 |
| 1M returni | -0.18% | -4.37% |
| 6M returni | +29.06% | +15.99% |
| 1Y returni | +18.88% | +31.15% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABBV | KO |
|---|---|---|
| 1Y ago | $11.88K (+18.8%) started 2025-09-22 | $13.16K (+31.6%) started 2025-09-22 |
| 5Y ago | $33.24K (+232.4%) started 2021-09-23 | $20.01K (+100.1%) started 2021-09-23 |
| 10Y ago | $92.24K (+822.4%) started 2016-09-23 | $36.27K (+262.7%) started 2016-09-23 |
Hypothetical — past performance does not guarantee future results.
| Metric | ABBV | KO |
|---|---|---|
| Market capi | $454.36B | $385.77B |
| Trailing P/Ei | 72.43 | 26.92 |
| Forward P/Ei | 15.79 | 25.43 |
| Price/Salesi | 5.85 | 6.55 |
| EV/Revenuei | 8.06 | 8.29 |
| Analyst targeti | $277.31 | $94.70 |
| Target upsidei | +7.85% | +5.62% |
| Metric | ABBV | KO |
|---|---|---|
| Revenue growthi | 10.20% | 6.70% |
| Earnings growthi | 290.40% | 16.90% |
| EPS growthi | +290.40% | +16.90% |
| FCF margini | +26.20% | +10.41% |
| Operating margini | 40.03% | 34.87% |
| Profit margini | 9.80% | 28.56% |
| ROIC proxyi | 6225.00% | 42.05% |
| Return on equityi | 6225.00% | 42.05% |
| Dividend yieldi | 2.69% | 2.36% |
| Payout ratioi | 190.40% | 62.46% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.28 | 0.34 |
| Debt/equityi | 4789.60 | 115.52 |
| Current ratioi | 0.81 | 1.30 |
| Quick ratioi | 0.49 | 0.80 |
Over the past year, ABBV and KO have moved weakly in the same direction (correlation of 0.33), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ABBV | KO |
|---|---|---|---|
| 1Y | Growthi | +18.82% | +31.58% |
| CAGRi | +18.85% | +31.64% | |
| Volatilityi | 26.48% | 18.86% | |
| Sharpe ratioi | 0.62 | 1.32 | |
| Sortino ratioi | 0.94 | 2.19 | |
| Max drawdowni | 19.23% | 8.50% | |
| Current drawdowni | 0.56% | 5.29% | |
| Avg drawdowni | 7.70% | 2.78% | |
| Ulcer Indexi | 9.02% | 3.61% | |
| Max daily dropi | 5.20% | 3.96% | |
| Max wkly dropi | 8.49% | 5.54% | |
| 5Y | Growthi | +184.61% | +79.13% |
| CAGRi | +23.28% | +12.37% | |
| Volatilityi | 23.38% | 16.72% | |
| Sharpe ratioi | 0.83 | 0.52 | |
| Sortino ratioi | 1.15 | 0.75 | |
| Max drawdowni | 21.92% | 17.27% | |
| Current drawdowni | 0.56% | 5.29% | |
| Avg drawdowni | 8.03% | 4.70% | |
| Ulcer Indexi | 9.98% | 6.06% | |
| Max daily dropi | 12.57% | 6.96% | |
| Max wkly dropi | 17.30% | 7.43% | |
| 10Y | Growthi | +490.01% | +166.76% |
| CAGRi | +19.43% | +10.31% | |
| Volatilityi | 26.03% | 18.45% | |
| Sharpe ratioi | 0.64 | 0.38 | |
| Sortino ratioi | 0.90 | 0.54 | |
| Max drawdowni | 45.09% | 36.99% | |
| Current drawdowni | 0.56% | 5.29% | |
| Avg drawdowni | 11.54% | 5.57% | |
| Ulcer Indexi | 15.58% | 7.86% | |
| Max daily dropi | 16.25% | 9.67% | |
| Max wkly dropi | 19.39% | 20.98% |
| Category | ABBV | KO |
|---|---|---|
| Company | AbbVie | Coca-Cola |
| Sector | Healthcare | Consumer Defensive |
| Industry | Drug Manufacturers - General | Beverages - Non-Alcoholic |
| Core business | AbbVie is a biopharmaceutical company that spun off from Abbott Laboratories in 2013. After years of depending on Humira, which lost patent exclusivity and now faces steep biosimilar erosion, the company has successfully pivoted its immunology business toward two newer drugs, Skyrizi and Rinvoq, which together generate more revenue than Humira ever did at its peak. AbbVie also has a growing presence in aesthetics (Botox Cosmetic, Juvederm), neuroscience, and oncology. | Coca-Cola is the world's largest beverage company, selling sparkling soft drinks, water, juices, teas, and coffee across more than 200 countries through a capital-light franchise bottling model. The company owns or licenses more than 200 brands, including Coca-Cola, Sprite, Fanta, Minute Maid, and Costa Coffee, and continues to diversify beyond carbonated soft drinks into water, sports drinks, and alcohol-adjacent ready-to-drink categories. |
| Investor focus | Dividend Growth + Pipeline Execution | Dividend Stability + Global Brand Moat |
- Skyrizi and Rinvoq have more than replaced lost Humira revenue and are still growing at double-digit rates
- Diversified portfolio across immunology, neuroscience, aesthetics, and oncology reduces single-drug concentration risk
- Dividend King-track record with decades of consecutive increases, backed by strong free cash flow
- Unmatched global distribution network and brand recognition create a durable competitive moat
- Capital-light franchise bottling model generates high margins and consistent free cash flow
- Dividend King with over six decades of consecutive annual dividend increases
- Humira revenue continues to decline sharply as biosimilar competition matures
- Patent cliffs are a recurring risk for any pharma business — Skyrizi and Rinvoq will eventually face their own exclusivity expirations
- Elevated debt load from the Allergan acquisition constrains capital allocation flexibility
- Slowing volume growth in mature markets as consumers shift away from sugary sparkling beverages
- Currency headwinds from a large international revenue base can pressure reported results
- Regulatory and public health pressure (sugar taxes, health trends) targeting sparkling soft drinks
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.